| [1] |
Yanagisawa M, Massaki T. Molecular biology and biochemistry of the endothelins [J]. Trends Pharmacol Sci, 1989, 10(9): 374-378.
|
| [2] |
张珂，陈鹊汀，王晓冬，等．内皮素受体的分布及其生物功能[J]．医学研究与教育，2014，31(3):76-81.
|
| [3] |
Houde M, Desbiens L, D′Orléans－Juste P. Endothelin－1: biosynthesis, signaling and vasoreactivity [J]. Adv Pharmacol, 2016, 77: 143-175.
|
| [4] |
邵子月，史虓悦，陈磊，等．内皮素与高血压相关性的研究进展[J]．中国现代医药杂志，2017，19(8):92-94.
|
| [5] |
梁荣章，吴永泉，邓朝胜．内皮素通路在靶向治疗慢性血栓栓塞性肺动脉高压中的作用及机制[J]．中华高血压杂志，2018，26(10):919-922.
|
| [6] |
Gohar EY, Giachini FR, Pollock DM, et al. Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases [J]. Life Sci, 2016, 15(159): 20-29.
|
| [7] |
Drexler H, Hornig B. Endothelial dysfunction in human disease [J]. J Mol Cell Cardiol, 1999, 31(1): 51-60.
|
| [8] |
史小映，张玉顺，龙昌柏．CTGF与低氧性肺血管重构的关系及波生坦的调控作用[J]. 临床医学研究与实践，2018，3(33):12-14, 25.
|
| [9] |
Trindade M, Oigman W, Fritsch Neves M. Potential role of endothelin in early vascular aging [J]. Curr Hypertens Rev, 2017, 13(1): 33-40.
|
| [10] |
王琪，程兆忠，王镜銮，等．内皮素－1在肺动脉高压发病中作用的研究进展[J]．心血管病防治知识(学术版)，2018，(4):93-96.
|
| [11] |
Boesen EI. Endothelin receptors, renal effects and blood pressure [J]. Curr Opin Pharmacol, 2015, 21: 25-34.
|
| [12] |
张洁，高秀林．内皮素及其受体拮抗剂对慢性肾脏病的影响[J]．中华保健医学杂志，2010，12(2):147-149.
|
| [13] |
范景如，郭舜奇．内皮素受体拮抗剂在高血压治疗中的研究进展[J]．中华高血压杂志，2017，25(7):632-635.
|
| [14] |
赵狄，叶鹏，Dhaun N，et al.慢性肾脏病患者血压与动脉僵硬度的昼夜变化：内皮素1的作用[J]．中华高血压杂志，2014，22(7):685.
|
| [15] |
Larivière R, Gauthier－Bastien A, Ung RV, et al. Endothelin type A receptor blockade reduces vascular calcification and inflammation in rats with chronic kidney disease [J]. J Hypertens, 2017, 35(2): 376-384.
|
| [16] |
王勇，吴俊姝，常淑萍．慢性肾脏病患者血清内皮素和一氧化氮水平变化的研究[J]．山西医药杂志(下半月刊)，2012，41(8):810-811.
|
| [17] |
Garsen M, Lenoir O, Rops AL, et al. Endothelin－1 induces proteinuria by heparanase－mediated disruption of the glomerular glycocalyx [J]. J Am Soc Nephrol, 2016, 27(12): 3545-3551.
|
| [18] |
Neuhofer W, Pittrow D. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence [J]. Eur J Clin Invest, 2009, 39(Suppl 2): 50-67.
|
| [19] |
Seccia TM, Caroccia B, Gioco F, et al. Endothelin-1 drives epithelial－mesenchymal transition in hypertensive nephroangiosclerosis [J]. J Am Heart Assoc, 2016, 5(7): e003888.
|
| [20] |
Coelho SC, Berillo O, Caillon A, et al. Three－month endothelial human endothelin－1 overexpression causes blood pressure elevation and vascular and kidney injury [J]. Hypertension, 2017, 71(1): 208-216.
|
| [21] |
Tobe S, Kohan DE, Singarayer R. Endothelin receptor antagonists: new hope for renal protection? [J]. Curr Hypertens Rep, 2015, 17(7): 57.
|
| [22] |
Davenport AP, Hyndman KA, Dhaun N. et al. Endothelin [J]. Pharmacol Rev, 2016, 68(2): 357-418.
|
| [23] |
Correale M, Ferraretti A, Monaco I, et al. Endothelin－receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? [J]. Vasc Health Risk Manag, 2018, 14: 253-264.
|
| [24] |
Yuan W, Cheng G, Li B, et al. Endothelin－receptor antagonist can reduce blood pressure in patients with hypertension: a meta－analysis [J]. Blood Press, 2017, 26(3): 139-149.
|
| [25] |
宋洁，余再新．内皮素受体拮抗剂在肺动脉高压治疗中的应用[J]．临床药物治疗杂志，2013，11(6):5-10.
|
| [26] |
Raina A, Horn ET, Benza RL. The pathophysiology of endothelin in complications after solid organ transplantation: a potential novel therapeutic role for endothelin receptor antagonists [J]. Transplantation, 2012, 94(9): 885-893.
|
| [27] |
Belge C, Delcroix M. Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience [J]. Ther Adv Respir Dis, 2019, 13: 1753466618823440.
|
| [28] |
顾智淳，沈节艳，刘晓琰，等．新型内皮素受体拮抗剂马西替坦：治疗肺动脉高压的一线药物[J]．中国新药与临床杂志，2015，34(2):102-106.
|
| [29] |
Steven S, Oelze M, Hausding M, et al. The Endothelin receptor antagonist macitentan improves isosorbide－5－mononitrate (ISMN) and isosorbide dinitrate (ISDN) induced endothelial dysfunction, oxidative stress, and vascular inflammation [J]. Oxid Med Cell Longev, 2018, 2018: 7845629.
|
| [30] |
Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin－angiotensin system blockade reduces albuminuria in diabetic nephropathy [J]. J Am Soc Nephrol, 2011, 22(4): 763-772.
|
| [31] |
Boels MG, Avramut MC, Koudijs A, et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy [J]. Diabetes, 2016, 65(8): 2429-2439.
|
| [32] |
Koomen JV, Stevens J, Mostafa NM, et al. Defining the optimal dose of atrasentan by evaluating the exposure－response relationships of albuminuria and bodyweight [J]. Diabetes Obes Metab, 2018, 20(8): 2019-2022.
|
| [33] |
Mann JF, Green D, Jamerson K, et al. Avosentan for Overt Diabetic Nephropathy [J]. J Am Soc Nephrol, 2010, 21(3): 527-535.
|
| [34] |
Weber MA, Black H, Bakris G, et al. A selective endothelin－receptor antagonist to reduce blood pressure in patients with treatment－resistant hypertension：a randomised，double－blind，placebo－controlled trial [J]. Lancet, 2009, 374(9699): 1423-1431.
|
| [35] |
Wei A, Gu Z, Li J, et al. Clinical adverse effects of endothelin receptor antagonists: insights from the meta－analysis of 4894 patients from 24 randomized double－blind placebo－controlled clinical trials [J]. J Am Heart Assoc, 2016, 5(11): e003896.
|
| [36] |
Vaněcková I, Hojná S, Kadlecová M, et al. Renoprotective effects of ET(A) receptor antagonists therapy in experimental non－diabetic chronic kidney disease: Is there still hope for the future? [J]. Physiol Res, 2018, 67(Suppl 1): S55-S67.
|
| [37] |
Gabbay E, Fraser J, Mcneil K. Review of bosentan in the management of pulmonary arterial hypertension [J]. Vasc Health Risk Manag, 2007, 3(6): 887-900.
|
| [38] |
US Food and Drug Administration. FDA drug safety communication: liver injury warning to be removed from Letairis (ambrisentan) tablets [EB/OL]. 2011:
URL
|
| [39] |
Mucke HA. Small－molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas [J]. IDrugs, 2009, 12(6): 366-375.
|